In line with their expanded collaboration to advance the development of alpibectir for the treatment of tuberculosis, GSK has taken an equity stake in BioVersys, joining new and existing investors in the series C extension round. The company raised CHF 12.3 million, bringing the total proceeds in this round to CHF 44.9 million. The funds will fuel the clinical development of BioVersys’ portfolio.
